In the realm of chemical synthesis, particularly within the pharmaceutical sector, precise identification and understanding of chemical intermediates are paramount. CAS number 76513-69-4 refers to 2-(Trimethylsilyl)ethoxymethyl Chloride, a compound that has carved out a significant niche due to its utility as a foundational building block in various synthetic pathways. Its primary importance is recognized in the creation of advanced pharmaceutical ingredients, most notably Ruxolitinib, a drug instrumental in treating serious blood disorders.

The chemical identity of 2-(Trimethylsilyl)ethoxymethyl Chloride, often abbreviated as SEM-CHLORIDE, is defined by its specific molecular structure which imparts particular reactivity. This reactivity is skillfully harnessed by synthetic chemists to introduce specific functional groups or to build complex molecular frameworks. Its application as a pharmaceutical intermediate means that rigorous quality control and a deep understanding of its chemical behavior are essential for successful downstream synthesis.

The broader field of chemical medicine benefits from intermediates like SEM-CHLORIDE, as they facilitate the development of new therapeutic agents. Whether used in the synthesis of established drugs or in the research and development of novel compounds, its role is consistently critical. The chemical industry continuously works to optimize the production of such intermediates, ensuring purity, yield, and cost-effectiveness to meet the demands of pharmaceutical manufacturers.

Delving into the properties of 2-(Trimethylsilyl)ethoxymethyl Chloride reveals its nature as a liquid compound, readily handled under controlled laboratory conditions. Its synonyms, such as 2-(Chloromethoxy)Ethyltrimethylsilane, further highlight its chemical composition and potential reactivity. The reliable sourcing of this chemical is a key aspect of the pharmaceutical supply chain, ensuring that drug production pipelines remain uninterrupted.

For researchers and manufacturers alike, comprehending the specific applications of CAS 76513-69-4 is crucial. Its well-established use in the synthesis of Ruxolitinib is a major driver of demand, but its potential extends to other areas of organic synthesis where its unique properties can be exploited. The continued exploration of its chemical potential promises further advancements in the field of chemical medicine.